MedTrace Logo

Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

NCT02684708 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2921

Last updated 2026-03-31

No results posted yet for this study

Summary

The EuroNet-PHL-C2 trial is an international, multicentre, randomised controlled trial with the aims to reduce the indication for radiotherapy in newly diagnosed patients with classical Hodgkin lymphoma without compromising cure rates and to investigate a chemotherapy intensification randomisation in intermediate and advanced classical Hodgkin lymphoma to compensate for reduction in radiotherapy.

Conditions

  • Classical Hodgkin Lymphoma

Interventions

DRUG

cyclophosphamide, vincristine, prednisone, dacarbazine

28-day chemotherapy cycle

DRUG

cyclo, vcr, pred, dacarb,etop and doxo

21-day chemotherapy cycle

Sponsors & Collaborators

  • Deutsche Krebshilfe e.V., Bonn (Germany)

    collaborator OTHER

  • Euronet Worldwide

    collaborator OTHER

  • University of Giessen

    lead OTHER

Principal Investigators

  • Dieter Koerholz, MD · Justus-Liebig University of Giessen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-01
Primary Completion
2024-10-31
Completion
2025-10-31

Countries

  • Australia
  • Austria
  • Belgium
  • Czechia
  • Denmark
  • France
  • Germany
  • Ireland
  • Israel
  • Italy
  • Netherlands
  • New Zealand
  • Norway
  • Poland
  • Slovakia
  • Spain
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02684708 on ClinicalTrials.gov